Novel Mechanisms for the Antifibrotic Action of Nintedanib

Idiopathic pulmonary fibrosis (IPF) is a disease with relentless course and limited therapeutic options. Nintedanib (BIBF-1120) is a multiple tyrosine kinase inhibitor recently approved by the U.S. Food and Drug Administration for the treatment of IPF. The precise antifibrotic mechanism(s) of action...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Respir Cell Mol Biol
Main Authors: Rangarajan, Sunad, Kurundkar, Ashish, Kurundkar, Deepali, Bernard, Karen, Sanders, Yan Y., Ding, Qiang, Antony, Veena B., Zhang, Jianhua, Zmijewski, Jaroslaw, Thannickal, Victor J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Thoracic Society 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742925/
https://ncbi.nlm.nih.gov/pubmed/26072676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1165/rcmb.2014-0445OC
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados